The risk of hemorrhagic conversion after stroke ( HR : @ , @ % CI : @ to @ ; p = @ ) or death ( HR : @ , @ % CI : @ to @ ; p = @ ) during follow-up was not significantly increased with vorapaxar in patients who had a new ischemic stroke ( n = @ ) .